{
    "root": "3467a30a-b7aa-0c26-e063-6294a90af6bf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pantoprazole Sodium",
    "value": "20250505",
    "ingredients": [
        {
            "name": "CALCIUM STEARATE",
            "code": "776XM7047L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_190296"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "SODIUM CARBONATE",
            "code": "45P3261C7T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29377"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_168426"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "ISOPROPYL ALCOHOL",
            "code": "ND2M416302",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "BUTYL ALCOHOL",
            "code": "8PJ61P6TS3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PANTOPRAZOLE SODIUM",
            "code": "6871619Q5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50270"
        }
    ],
    "indications": {
        "text": "pantoprazole sodium delayed-release tablets indicated :",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "* controlled extend beyond 12 months full prescribing information instructions indication dose frequency short-term treatment erosive esophagitis associated gerd ( 2.1 ) adults 40 mg daily 8 wks children ( 5 years older ) \u2265 15 kg < 40 kg 20 mg daily 8 wks \u2265 40 kg 40 mg maintenance healing erosive esophagitis ( 2.1 ) adults 40 mg daily * pathological hypersecretory conditions including zollinger-ellison syndrome ( 2.1 ) adults 40 mg twice daily",
        "doid_entities": [
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            },
            {
                "text": "gerd (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "zollinger-ellison syndrome (DOID:0050782)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050782"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "zollinger-ellison syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_913"
            }
        ]
    },
    "warningsAndPrecautions": "pantoprazole sodium delayed-release tablets usp , 40 mg yellow colored , oval shaped , biconvex , enteric-coated tablets imprinted \u2018 \u2019 \u2018 52 \u2019 brown ink one side plain side . ndc : 70518-0860-00 ndc : 70518-0860-01 packaging : 90 1 bottle plastic packaging : 28 1 blister pack store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "pantoprazole sodium contraindicated patients known hypersensitivity component formulation substituted benzimidazole . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6 ) ] . proton pump inhibitors ( ppis ) , including pantoprazole sodium , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Pantoprazole sodium \u00a0delayed-release tablets\u00a0are indicated for:",
    "contraindications_original": "* Controlled studies did not extend beyond 12 months See full prescribing information for administration instructions Indication Dose Frequency Short-Term Treatment of Erosive Esophagitis Associated With GERD ( 2.1 ) Adults 40 mg Once Daily for up to 8 wks Children (5 years and older) \u2265 15 kg to < 40 kg 20 mg Once Daily for up to 8 wks \u2265 40 kg 40 mg Maintenance of Healing of Erosive Esophagitis ( 2.1 ) Adults 40 mg Once Daily* Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome ( 2.1 ) Adults 40 mg Twice Daily",
    "warningsAndPrecautions_original": "Pantoprazole Sodium Delayed-Release Tablets\u00a0USP, 40 mg\u00a0are yellow colored, oval shaped, biconvex, enteric-coated tablets imprinted with \u2018I\u2019 and \u201852\u2019 with brown ink on one side and plain on other side.\n                  NDC: 70518-0860-00\n                  NDC: 70518-0860-01\n                  PACKAGING: 90 in 1 BOTTLE PLASTIC\n                  PACKAGING: 28 in 1 BLISTER PACK\n                  \n                  Store at\u00a020\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Pantoprazole sodium is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria\n  \n   [see\n                        \n                           Warnings and Precautions (5.2),\n  \n   \n                        \n                           Adverse Reactions (6)].\n  \n   \n                     \n                     Proton pump inhibitors (PPIs), including pantoprazole sodium, are contraindicated in patients receiving rilpivirine-containing products\n  \n   [see\n   \n    Drug Interactions (7)]\n  \n   .",
    "drug": [
        {
            "name": "Pantoprazole Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50270"
        }
    ]
}